Drug Profile
Research programme: S-nitrosothiol modulating agents - Laurel Venture Capital
Alternative Names: GSNORi's - Alpine Immune Sciences; N 6547; N 91121; N 91138; N 91169; N6022 analogues; S nitrosoglutathione reductase inhibitors - Alpine Immune SciencesLatest Information Update: 26 Jul 2018
Price :
$50
*
At a glance
- Originator NitroMed
- Developer Alpine Immune Sciences
- Class Small molecules
- Mechanism of Action Cystic fibrosis transmembrane conductance regulator modulators; Glutathione-independent formaldehyde dehydrogenase inhibitors; Nitric oxide stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Chronic obstructive pulmonary disease; Cystic fibrosis; Inflammatory bowel diseases; Respiratory tract disorders
Most Recent Events
- 20 Jul 2018 Laurel Venture Capital acquires global rights for S-nitrosoglutathione reductase (GSNOR) assets from Alpine Immune Sciences
- 04 Nov 2017 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in USA (IV, Injection)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in USA (PO)